BioSpace News Archive

Applied Genetic Technologies Corporation (Nasdaq: AGTC), today announced that Jill Dolgin, PharmD, Executive Director of Global Patient Advocacy, and Halley Losekamp, Director of Patient Enrollment, will participate as speakers at the Clinical Trials in Rare Diseases Conference,

Flamingo Therapeutics, Inc., a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that it has entered into an agreement with Ionis Pharmaceuticals to develop RNA-targeted therapies to treat various forms of cancer.

INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world’s only in vivo culture system (IVC), INVOcell®, an affordable and effective infertility treatment, announced today that it has completed the acquisition of a Canadian-based entity that was originally formed to offer INVOcell in Canada.

Seven Bridges, the industry-leading bioinformatics ecosystem provider, and Scripps Research have been awarded a $7.5M contract to develop a federated data ecosystem for the National Institute of Allergy and Infectious Diseases (NIAID) under a project titled the NIAID Data Ecosystem (NDE).

Gaumard Scientific Co., today commented on the recent findings published in Obstetrics and Gynecology documenting a reduction of malpractice claims rates by obstetrician-gynecologists who participated in medical simulation training.

Seelos Therapeutics, Inc. today announced that it will participate in the M-Vest Advances in Mental Health, Psychedelic and Non-Psychedelic Virtual Conference on September 22nd and the Cantor Virtual Global Healthcare Conference, September 27th-30th, 2021.

Ashvattha Therapeutics today announced that Jeffrey Cleland, Ph.D., Chairman, CEO and President will be presenting at the following upcoming virtual and in-person investor conferences: HC Wainwright 23rd Annual Global Investment Conference

Syros Pharmaceuticals today announced that the first patient has been dosed in the SELECT-AML-1 clinical trial of tamibarotene, its first-in-class selective retinoic acid receptor alpha (RARα) agonist, in combination with venetoclax and azacitidine.

Aytu BioPharma, Inc. today announced the formation of its Scientific Advisory Board, chaired by Dr. Hal Dietz, Professor of Genetic Medicine at the Johns Hopkins University School of Medicine.

Pieris Pharmaceuticals, Inc., a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced that members of the management team will participate in the following upcoming investor conferences.